Please assess the completion status of the following clinical trial:

Trial Title: Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female with a persisting pregnancy of unknown location:~* A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization.~* Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing \< 15% rise per day, or \< 50% fall between the first and last value.~* Patient is hemodynamically stable, hemoglobin \>10 mg/dL~* Greater than or 18 years of age~Exclusion Criteria:~* Hemodynamically unstable in need of acute treatment~* Most recent hCG \> 5000 mIU/mL~* Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion)~* Diagnosis of gestational trophoblastic disease~* Subject unwilling or unable to comply with study procedures~* Known hypersensitivity to MTX~* Presence of clinical contraindications for treatment with MTX~* Prior medical or surgical management of this gestation~* Subject unwilling to accept a blood transfusion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Expectant Management (Type: ACTIVE_COMPARATOR): Subjects will have their PPUL expectantly managed using serum hCG monitoring.
- Uterine evacuation with MTX for some (Type: ACTIVE_COMPARATOR): Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
- Empiric treatment with MTX for all (Type: ACTIVE_COMPARATOR): Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).